ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2016

The Chromatin Landscape Around the Juvenile Arthritis-Associated CXCR4 Locus Suggests Regulatory Functions and Genetic Roles in Both Innate and Adaptive Immunity

Laura Easton1, Evan Tarbell2, Kaiyu Jiang3, Kyle Mentkowski4, Shannon O'Leary5, Tao Liu5 and James Jarvis1, 1Pediatrics, University at Buffalo Jacobs School of Medicine & Biomedical Sciences, Buffalo, NY, 2Biochemistry, University at Buffalo, Buffalo, NY, 3Pediatrics, University at Buffalo, Buffalo, NY, 4Graduate Program in Biological Sciences, University at Buffalo Jacobs School of Medicine & Biomedical Sciences, Buffalo, NY, 5Genetics, Genomics, & Bioinformatics Program, University at Buffalo Jacobs School of Medicine & Biomedical Sciences, Buffalo, NY

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: genetic architecture and juvenile arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Pediatric Rheumatology – Basic Science Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: CXCR4 is a recently identified susceptibility locus for juvenile idiopathic arthritis (JIA). The index single nucleotide polymorphism (SNP) used to identify this locus, rs95338, lies in an intergenic region upstream of the CXCR4 gene, suggesting that this region has regulatory functions. We sought to gain biological insight into the association between JIA and the CXCR4 locus by examining the chromatin architecture within this locus, including the presence of epigenetically-marked regulatory elements, in relevant primary cells and cell lines.

Methods: Using the SNP Annotation and Proxy Search from the Broad Institute and standard computational methods, we first defined the linkage disequilibrium (LD) block containing the rs953387 SNP. We used BedTools to query ENCODE and Roadmap Epigenomics data to identify relevant functional epigenetic marks (e.g., H3K4me1/H3K27ac, and CTCF binding motifs) within the CXCR4 haplotype. For statistical analysis, each value was compared to the mean and standard deviation of 100 randomly generated files with the same number of peaks as the ENCODE file being examined. In addition, we used quantitative rtPCR analysis to confirm the presence of a non-coding, intergenic RNA transcript that we identified on RNAseq in neutrophils and assess the effects of treatment on expression of this transcript.

Results: The LD block for the rs953387 SNP comprises a genomic region of between 54,236 (r-squared of 0.9) and 69,609 bp (r-squared of 0.8) upstream from the coding region of the CXCR4 gene. This region contains 154 JIA associated SNPs that we recently identified using whole genome sequencing, in addition to >30 variants catalogued in 1000 Genome Project. Further analysis using ENCODE and Roadmap Epigenomics data demonstrate that the LD block (r2= 0.8) includes enrichment for H3K4me1 (poised enhancer) peaks compared to randomly generated peaks from hg19 genome in primary CD4+ T-cell lines and primary CD 15+ (neutrophil) cell lines, with the LD containing 12 and 15 peaks respectively. There are 6 H3K27ac (active enhancer) peaks in the LD block from primary CD4+ cell data, which is statistically higher than the random value. CHIPSeq data from neutrophils from our own lab shows multiple H3K4me1 and H3K27ac peaks in this LD block in addition to a noncoding (intergenic) RNA. The non-coding RNA was verified using rtPCR and showed changes in expression levels when neutrophils from children with active JIA were compared to those in clinical remission on medication. Further analysis identified H3K4me1, but not H3K27ac, enrichment in CD14+ monocytes and CD20+ B cells as well as other T- lymphocyte cell lines.

Conclusion: The LD blocking containing the rs953387 SNP lies upstream of the CXCR4 gene itself and is likely a regulatory region. This region contains enhancer elements in multiple immune cell lines, especially in CD4+ primary T-cells and CD15+ neutrophils as well as an intergenic non-coding RNA. The regulatory function of this region may or may not relate to the CXCR4 gene itself, as enhancers do not always regulate the nearest gene. These findings corroborate our earlier studies demonstrating that the genetics of JIA impinges almost exclusively on gene regulatory functions.


Disclosure: L. Easton, None; E. Tarbell, None; K. Jiang, None; K. Mentkowski, None; S. O'Leary, None; T. Liu, None; J. Jarvis, None.

To cite this abstract in AMA style:

Easton L, Tarbell E, Jiang K, Mentkowski K, O'Leary S, Liu T, Jarvis J. The Chromatin Landscape Around the Juvenile Arthritis-Associated CXCR4 Locus Suggests Regulatory Functions and Genetic Roles in Both Innate and Adaptive Immunity [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/the-chromatin-landscape-around-the-juvenile-arthritis-associated-cxcr4-locus-suggests-regulatory-functions-and-genetic-roles-in-both-innate-and-adaptive-immunity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-chromatin-landscape-around-the-juvenile-arthritis-associated-cxcr4-locus-suggests-regulatory-functions-and-genetic-roles-in-both-innate-and-adaptive-immunity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology